Price Performance of Cancer Genetics, Inc. (CGIX)
Cancer Genetics, Inc. (NASDAQ:CGIX) has had quite a year when it comes to price performance. This company’s stock managed to rise to its 1-Year High price of $2.20 on 03/19/18, and it go to its lowest price in the past year, which was $0.20 on 12/12/18.
At the end of the most recent trading day, Cancer Genetics, Inc. closed at $0.26. The stock began the trading session at $0.26 and hit a high of $0.28. The lowest price during the trading day was $0.25.
The shares of this company, which operates in the healthcare sector, reached a trading volume of about 1,643,021 throughout the day, which was clearly lower than the average daily volume for these shares.
At the time of writing, this publicly-traded organization holds a total market value of 10.64M, with 218 employees on its payroll.
Continuing ahead, if we consider what stock trading experts have to say currently, for Cancer Genetics, Inc. (NASDAQ:CGIX), the mean rating for this stock is 2.50. How is that calculated? Well, 0 analysts have given this company a BUY rating, 1 is rated it as OUTPERFORM, 1 has recommended that investors HOLD, 0 are considering it an UNDERPERFORM and 0 have recommended that owners of these shares SELL.
A month ago, 0 analysts thought this stock was a BUY, 1 of them posted an OUTPERFORM rating, 1 analysts recommended to HOLD this stock, 0 of them provided an underperform rating and 0 rated it as a Sell.
For CGIX stock, the reported Earnings Per Share trailing twelve months is sitting at 72.40%. Meanwhile, operating margin is currently observed to be -98.60% and its Gross Margin trailing twelve months is 29.60%.
This company’s 100-day moving average was 0.55, while its price change was posted at -0.78. Similarly, Cancer Genetics, Inc. (NASDAQ:CGIX) experienced a 100-day Percent movement of -75.00% with a trading volume reaching 1,366,743.
Continuing to look at similarly important data, this stock’s distance from its 200-day Simple Moving Average, or SMA 200, is -65.95% at the time of writing. This organization’s revenue over the trailing twelve months (TTM) of active operations is 28.20M, considering the fact that it was able to rack up the income of -$9.30M through that period of time.
A solid method of understanding a company’s financial power is to look at its Total Debt to Equity Ratio or (D/E) Ratio, which is found by dividing a company’s current total liabilities by its stockholders’ equity. This metric just illustrates how much debt an organization is using to support its assets in relation to how much its shareholder’s equity is worth. CGIX’s Total Dept/Eq ratio is sitting at 1.29 at the time of writing, while its long-term Dept/Eq ratio is 0.05
While maintaining our attention on the Technical analysis of Cancer Genetics, Inc. (NASDAQ:CGIX), during the last 50 days, its Raw Stochastic average was observed 12.24%, representing a downgrade from this organization’s 20-day Raw Stochastic average – which was posted 21.21%. During the last 20-days time span, this firm’s Stochastic %K was 27.54% and its Stochastic %D was noted 28.47%.
While taking a glance at the past price performance of Cancer Genetics, Inc. (NASDAQ:CGIX), we can observe multiple moving trends. This particular stock’s current year-to-date (YTD) price performance is standing at 6.40%. Meanwhile, during the past six months of trading, this stock has deteriorated to -73.72%, along with a full-year performance of -86.45%. This company’s shares increased nearly 4.77% during the last 7-day stretch and up -0.19% over the last 30 days.